Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4614 Target Snapshot

Bifunctional dihydrofolate reductase-thymidylate synthase · SINGLE PROTEIN · Leishmania major

134Compounds
12Assays
5Approved Drugs
124.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P07382. Use UniProt P07382 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P07382 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional dihydrofolate reductase-thymidylate synthase as ChEMBL target CHEMBL4614, mapped to UniProt P07382. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional dihydrofolate reductase-thymidylate synthase
SINGLE PROTEIN · Leishmania major
As of 2026-09-13
ChEMBL target ID
CHEMBL4614
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P07382
Bifunctional dihydrofolate reductase-thymidylate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bifunctional dihydrofolate reductase-thymidylate synthase is the right protein anchor across sources, using UniProt P07382 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBifunctional dihydrofolate reductase-thymidylate synthase
UniProt AccessionP07382
Component TypeProtein
Sequence Length520 aa

Bifunctional dihydrofolate reductase-thymidylate synthase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Bifunctional dihydrofolate reductase-thymidylate synthase, mapped to UniProt P07382. Sequence length is 520 aa.

Mapped IDP07382
Review nameBifunctional dihydrofolate reductase-thymidylate synthase
OrganismLeishmania major
Clinical Profile

Clinical Phase Distribution

5
Approved
Assay Mix

Activity Type Distribution

IC5067.0
KI51.0
KD6.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL34259 9.89 Ki 0.1288 Approved
CHEMBL34259 8.64 IC50 2.29 Approved
CHEMBL6054471 8.43 IC50 3.72 Preclinical
CHEMBL4544467 8.13 IC50 7.41 Preclinical
CHEMBL4456834 8.12 IC50 7.59 Preclinical
CHEMBL5786336 8.1 IC50 7.94 Preclinical
CHEMBL20424 7.77 Ki 16.98 Preclinical
CHEMBL20587 7.68 Ki 20.89 Preclinical
CHEMBL533684 7.6 IC50 25.0 Preclinical
CHEMBL5759188 7.54 IC50 28.8 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
16
5.5
23
6.0
23
6.5
10
7.0
5
7.5
4
8.0
1
8.5
0
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

TRIMETHOPRIM
CHEMBL22
Approved 1973
METHOTREXATE
CHEMBL34259
Approved 1953
Assay Landscape

Assay Landscape

12
Total Assays
121
Tested Compounds
1
Assay Types
Binding — 12 assays, 121 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 11 87 6.3
cell-based format 1 34 5.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine